SNT 2.22% 4.4¢ syntara limited

Ann: Preliminary Final Report, page-2

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 5,800 Posts.
    lightbulb Created with Sketch. 706
    https://www.pharmaceutical-technology.com/comment/current-future-cystic-fibrosis-market/?cf-view

    Vertex has unbelievable market share in cystic fibrosis treatment

    But at least Pharmaxis is well recognised

    keep up the good work Pharmaxis!!!
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.